Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Docta Complutense
Publicación Artículo científico (JournalArticle)

Prodromic Inflammatory–Oxidative Stress in Peritoneal Leukocytes of Triple-Transgenic Mice for Alzheimer’s Disease

  • Ceprián, Noemí
  • Martínez De Toda Cabeza, Irene
  • Maté, Ianire
  • Garrido, Antonio
  • Giménez Llort, Lydia
  • Fuente Del Rey, María Mónica De La
Inflammatory–oxidative stress is known to be pivotal in the pathobiology of Alzheimer’s disease (AD), but the involvement of this stress at the peripheral level in the disease’s onset has been scarcely studied. This study investigated the pro-inflammatory profile and oxidative stress parameters in peritoneal leukocytes from female triple-transgenic mice for AD (3xTgAD) and non-transgenic mice (NTg). Peritoneal leukocytes were obtained at 2, 4, 6, 12, and 15 months of age. The concentrations of TNFα, INFγ, IL-1β, IL-2, IL-6, IL-17, and IL-10 released in cultures without stimuli and mitogen concanavalin A and lipopolysaccharide presence were measured. The concentrations of reduced glutathione (GSH), oxidized glutathione (GSSG), lipid peroxidation, and Hsp70 were also analyzed in the peritoneal cells. Our results showed that although there was a lower release of pro-inflammatory cytokines by 3xTgAD mice, this response was uncontrolled and overstimulated, especially at a prodromal stage at 2 months of age. In addition, there were lower concentrations of GSH in leukocytes from 3xTgAD and higher amounts of lipid peroxides at 2 and 4 months, as well as, at 6 months, a lower concentration of Hsp70. In conclusion, 3xTgAD mice show a worse pro-inflammatory response and higher oxidative stress than NTg mice during the prodromal stages, potentially supporting the idea that Alzheimer’s disease could be a consequence of peripheral alteration in the leukocyte inflammation–oxidation state.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Prodromic Inflammatory-Oxidative Stress in Peritoneal Leukocytes of Triple-Transgenic Mice for Alzheimer's Disease

  • Ceprián, Noemí|||0000-0001-7028-3083
  • Martínez de Toda, Irene|||0000-0002-1707-487X
  • Maté, Ianire|||0000-0003-0566-2508
  • Garrido, Antonio|||0000-0003-3026-3330
  • Gimenez-Llort, Lydia|||0000-0002-4091-489X
  • De la Fuente, Mónica
Inflammatory-oxidative stress is known to be pivotal in the pathobiology of Alzheimer's disease (AD), but the involvement of this stress at the peripheral level in the disease's onset has been scarcely studied. This study investigated the pro-inflammatory profile and oxidative stress parameters in peritoneal leukocytes from female triple-transgenic mice for AD (3xTgAD) and non-transgenic mice (NTg). Peritoneal leukocytes were obtained at 2, 4, 6, 12, and 15 months of age. The concentrations of TNFα, INFγ, IL-1β, IL-2, IL-6, IL-17, and IL-10 released in cultures without stimuli and mitogen concanavalin A and lipopolysaccharide presence were measured. The concentrations of reduced glutathione (GSH), oxidized glutathione (GSSG), lipid peroxidation, and Hsp70 were also analyzed in the peritoneal cells. Our results showed that although there was a lower release of pro-inflammatory cytokines by 3xTgAD mice, this response was uncontrolled and overstimulated, especially at a prodromal stage at 2 months of age. In addition, there were lower concentrations of GSH in leukocytes from 3xTgAD and higher amounts of lipid peroxides at 2 and 4 months, as well as, at 6 months, a lower concentration of Hsp70. In conclusion, 3xTgAD mice show a worse pro-inflammatory response and higher oxidative stress than NTg mice during the prodromal stages, potentially supporting the idea that Alzheimer's disease could be a consequence of peripheral alteration in the leukocyte inflammation-oxidation state.
Repositori Obert UdL
Publicación Artículo científico (JournalArticle)

Lifelong treatment with atenolol decreases membrane fatty acid unsaturation and oxidative stress in heart and skeletal muscle mitochondria and improves immunity and behaviour, without changing mice longevity.

  • Pamplona Gras, Reinald
  • Portero Otín, Manuel
  • Naudí i Farré, Alba
  • Fuente, Monica de la
  • Barja, Gustavo
  • López Torres, Mónica
  • Mate, Ianire
  • Cruces, Julia
  • Gómez, José
  • Sánchez-Roman, Ines
  • Gómez Rodríguez, Alexia
The membrane fatty acid unsaturation hypothesis of aging and longevity is experimentally tested for the first time in mammals. Lifelong treatment of mice with the b1-blocker atenolol increased the amount of the extracellular-signal-regulated kinase signaling protein and successfully decreased one of the two traits appropriately correlating with animal longevity, the membrane fatty acid unsaturation degree of cardiac and skeletal muscle mitochondria, changing their lipid profile toward that present in much more longer-lived mammals. This was mainly due to decreases in 22:6n-3 and increases in 18:1n-9 fatty acids. The atenolol treatment also lowered visceral adiposity (by 24%), decreased mitochondrial protein oxidative, glycoxidative, and lipoxidative damage in both organs, and lowered oxidative damage in heart mitochondrial DNA. Atenolol also improved various immune (chemotaxis and natural killer activities) and behavioral functions (equilibrium, motor coordination, and muscular vigor). It also totally or partially prevented the aging-related detrimental changes observed in mitochondrial membrane unsaturation, protein oxidative modifications, and immune and behavioral functions, without changing longevity. The controls reached 3.93 years of age, a substantially higher maximum longevity than the best previously described for this strain (3.0 years). Side effects of the drug could have masked a likely lowering of the endogenous aging rate induced by the decrease in membrane fatty acid unsaturation. Weconclude that it is atenolol that failed to increase longevity, and likely not the decrease in membrane unsaturation induced by the drug., This investigation was supported by I + D grants from the Spanish Ministry of Science and Innovation (BFU2011-23888 to G.Barja); UCMGroups of Research (910379ENEROINN), BFU2011-30336, and RETICEF (RD 12/0043/0018) from ISCIII-FEDER of the European Union to M. De la Fuente; Spanish Ministry of Health (PI11/01532) to M.Portero Otin; and Spanish Ministry of Science and Innovation (BFU2009-11879) and the Generalitat of Catalonia (2009SGR735) to R. Pamplona.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Lifelong treatment with atenolol decreases membrane fatty acid unsaturation and oxidative stress in heart and skeletal muscle mitochondria and improves immunity and behaviour, without changing mice longevity.

  • Pamplona Gras, Reinald
  • Portero Otín, Manuel
  • Naudí i Farré, Alba
  • Fuente, Monica de la
  • Barja, Gustavo
  • López Torres, Mónica
  • Mate, Ianire
  • Cruces, Julia
  • Gómez, José
  • Sánchez-Roman, Ines
  • Gómez Rodríguez, Alexia
The membrane fatty acid unsaturation hypothesis of aging and longevity is experimentally tested for the first time in mammals. Lifelong treatment of mice with the b1-blocker atenolol increased the amount of the extracellular-signal-regulated kinase signaling protein and successfully decreased one of the two traits appropriately correlating with animal longevity, the membrane fatty acid unsaturation degree of cardiac and skeletal muscle mitochondria, changing their lipid profile toward that present in much more longer-lived mammals. This was mainly due to decreases in 22:6n-3 and increases in 18:1n-9 fatty acids. The atenolol treatment also lowered visceral adiposity (by 24%), decreased mitochondrial protein oxidative, glycoxidative, and lipoxidative damage in both organs, and lowered oxidative damage in heart mitochondrial DNA. Atenolol also improved various immune (chemotaxis and natural killer activities) and behavioral functions (equilibrium, motor coordination, and muscular vigor). It also totally or partially prevented the aging-related detrimental changes observed in mitochondrial membrane unsaturation, protein oxidative modifications, and immune and behavioral functions, without changing longevity. The controls reached 3.93 years of age, a substantially higher maximum longevity than the best previously described for this strain (3.0 years). Side effects of the drug could have masked a likely lowering of the endogenous aging rate induced by the decrease in membrane fatty acid unsaturation. Weconclude that it is atenolol that failed to increase longevity, and likely not the decrease in membrane unsaturation induced by the drug., This investigation was supported by I + D grants from the Spanish Ministry of Science and Innovation (BFU2011-23888 to G.Barja); UCMGroups of Research (910379ENEROINN), BFU2011-30336, and RETICEF (RD 12/0043/0018) from ISCIII-FEDER of the European Union to M. De la Fuente; Spanish Ministry of Health (PI11/01532) to M.Portero Otin; and Spanish Ministry of Science and Innovation (BFU2009-11879) and the Generalitat of Catalonia (2009SGR735) to R. Pamplona.